Board of Directors

Adam Koppel is a distinguished investor and strategic leader with more than 25 years of biopharmaceutical industry experience. He is a Partner on Bain Capital’s Life Sciences team and initially joined Bain Capital in 2003. Previously, Dr. Koppel was EVP of Corporate Development and Chief Strategy Officer at Biogen. In addition to Cardurion, he currently sits on the Board of Directors of Kailera Therapeutics and Areteia Therapeutics and serves on the Board of Trustees at Newton Wellesley Hospital. Dr. Koppel also co-chairs the Harvard Medical School Discovery Council and serves on the Mass General Brigham Innovation Growth Board. He received an M.D. and Ph.D. in Neuroscience from the University of Pennsylvania School of Medicine. Dr. Koppel also received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar, and graduated magna cum laude from Harvard University with an AB and AM in History and Science.